Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
As of close of business last night, Arcturus Therapeutics Holdings Inc’s stock clocked out at $25.57, down -3.98% from its previous closing price of $26.63. In other words, the price has decreased by -$3.98 from its previous closing price. On the day, 0.58 million shares were traded. ARCT stock price reached its highest trading level at $26.43 during the session, while it also had its lowest trading level at $25.44.
Ratios:
To gain a deeper understanding of ARCT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.72 and its Current Ratio is at 4.72. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Canaccord Genuity on December 13, 2023, initiated with a Buy rating and assigned the stock a target price of $90.
On July 24, 2023, William Blair started tracking the stock assigning a Outperform rating and target price of $71.
H.C. Wainwright Upgraded its Neutral to Buy on May 11, 2023, whereas the target price for the stock was revised from $19 to $51.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 25 ’24 when Chivukula Pad sold 17,435 shares for $35.02 per share. The transaction valued at 610,574 led to the insider holds 473,448 shares of the business.
Chivukula Pad sold 8,565 shares of ARCT for $299,839 on Mar 19 ’24. The Chief Scientific Officer & COO now owns 490,883 shares after completing the transaction at $35.01 per share. On Nov 01 ’23, another insider, Chivukula Pad, who serves as the Chief Scientific Officer & COO of the company, sold 5,000 shares for $18.72 each. As a result, the insider received 93,602 and left with 499,448 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARCT now has a Market Capitalization of 688221632 and an Enterprise Value of 426433760. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.28 while its Price-to-Book (P/B) ratio in mrq is 2.46. Its current Enterprise Value per Revenue stands at 2.557 whereas that against EBITDA is -5.667.
Stock Price History:
The Beta on a monthly basis for ARCT is 2.64, which has changed by -0.034365535 over the last 52 weeks, in comparison to a change of 0.23099434 over the same period for the S&P500. Over the past 52 weeks, ARCT has reached a high of $43.81, while it has fallen to a 52-week low of $17.52. The 50-Day Moving Average of the stock is -23.87%, while the 200-Day Moving Average is calculated to be -14.47%.
Shares Statistics:
It appears that ARCT traded 483.90K shares on average per day over the past three months and 445860 shares per day over the past ten days. A total of 26.83M shares are outstanding, with a floating share count of 24.56M. Insiders hold about 8.75% of the company’s shares, while institutions hold 93.43% stake in the company. Shares short for ARCT as of 1713139200 were 4613132 with a Short Ratio of 9.53, compared to 1710460800 on 4205886. Therefore, it implies a Short% of Shares Outstanding of 4613132 and a Short% of Float of 22.82.
Earnings Estimates
Arcturus Therapeutics Holdings Inc (ARCT) is currently under the scrutiny of 8.0 analysts, each contributing to the ongoing evaluation of its stock.On average, analysts expect EPS of -$1.19 for the current quarter, with a high estimate of -$0.84 and a low estimate of -$1.71, while EPS last year was $1.87. The consensus estimate for the next quarter is -$1.0, with high estimates of $0.22 and low estimates of -$1.78.
Analysts are recommending an EPS of between -$0.37 and -$5.97 for the fiscal current year, implying an average EPS of -$2.51. EPS for the following year is $0.22, with 9.0 analysts recommending between $9.92 and -$5.11.
Revenue Estimates
In the current quarter, 8 analysts expect revenue to total $17.54M. It ranges from a high estimate of $29.34M to a low estimate of $6M. As of the current estimate, Arcturus Therapeutics Holdings Inc’s year-ago sales were $79.73MFor the next quarter, 8 analysts are estimating revenue of $23.8M. There is a high estimate of $73.36M for the next quarter, whereas the lowest estimate is $6M.
A total of 9 analysts have provided revenue estimates for ARCT’s current fiscal year. The highest revenue estimate was $293.45M, while the lowest revenue estimate was $55.51M, resulting in an average revenue estimate of $146.3M. In the same quarter a year ago, actual revenue was $169.93MBased on 9 analysts’ estimates, the company’s revenue will be $250.59M in the next fiscal year. The high estimate is $771.01M and the low estimate is $111.72M.
